Level Zero Health, a healthtech startup with bases in London and San Francisco, has successfully secured £5.5 million in pre-seed funding to develop the world's largest hormone health dataset.

The investment round was led by the European venture capital firm Redalpine, with additional support from HAX (SOSV), Entrepreneur First, and various industry experts, showcasing confidence in the startup despite a challenging funding environment.

This funding will enable the creation of innovative DNA-based sensors designed for remote and continuous hormone monitoring, significantly improving upon traditional lab blood tests that only provide a one-time snapshot.

The company's sensors measure hormone levels through interstitial fluid using a wearable patch, akin to glucose monitors, and have achieved validation across 98% of the human clinical range within just one year.

Philip Kneis, an investor from Redalpine, expressed enthusiasm about the potential of continuous hormone measurement to revolutionize diagnostics and personalized health management.

The technology is anticipated to enhance patient access to care, lower healthcare costs, and improve the management of hormonal-based diseases and treatments.

To bolster its clinical oversight and credibility, Level Zero Health has established a top clinical advisory board featuring notable figures such as Aaron Styer and Joshua Klein.

The startup plans to utilize its funding for research and development, market entry, and team expansion in both the UK and US, initially focusing on B2B clinical applications with an eye toward potential B2C growth.

This groundbreaking technology aims to transform healthcare practices in critical areas such as IVF, menopause, and testosterone replacement therapy, alleviating the burdens associated with frequent invasive blood tests.

Founded by Ula Rustamova, a former Palantir tech lead, and Irene Jia, an expert in medical devices, Level Zero Health is at the forefront of innovating hormone monitoring technology to provide real-time insights into bodily chemistry.